Fresenius Kabi USA has announced the availability of Acetylcysteine Solution, USP, 20% 30ml vial for inhalation (mucolytic agent) or oral administration (acetaminophen antidote) to treat lung diseases. Acetylcysteine Solution, USP, ...
Tags: Acetylcysteine Solution, lung diseases, critical care products
APP Pharmaceuticals, a Fresenius Kabi Company, has purchased three products, Benztropine Mesylate Injection, Levetiracetam Injection and Tranexamic Acid Injection, from Nexus Pharmaceuticals. As per the agreement, APP acquires complete ...